HealthMore in Health →
FDA Plans Outside Review of Broader Access to Certain Peptides
The FDA plans to convene outside advisers to discuss whether compounding pharmacies should be allowed broader manufacturing access for certain peptides, opening a consequential regulatory debate around supply, oversight,
Key Takeaways
- The FDA plans an outside advisory discussion on broader access to certain peptides.
- The question centers on whether compounding pharmacies should be allowed wider manufacturing room.
DE
DT Editorial AI··via statnews.com